https://www.mbcalliance.org/wp-content/uploads/2023.04.05-CDK-4-6-1.jpg 667 1000 MBCA https://www.mbcalliance.org/wp-content/uploads/mbca-logo.png MBCA2023-04-05 12:00:342023-04-10 20:32:19Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Breast cancer outcomes improved with CDK4/6 inhibitor treatment
A study showed that people with HR-positive, HER2-negative metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy fared better than people who took hormone therapy alone. The drug combination improved progression-free survival (the length of time before cancer worsened or returned). After six years of treatment, overall survival was also better for those who took this drug combination compared to those who took hormone therapy alone.